益生菌和致病菌对肠道的黏附及其相互作用研究进展

探讨益生菌及致病菌对肠道上皮细胞的黏附机制,比较其黏附后的生物学效应差异,重点对二者之间的竞争性黏附作用进行了概述.在上述基础上对益生菌抑制致病菌的研究前景和发展趋势进行了展望.     

益生菌抗衰老作用机制研究进展

衰老会引起机体诸多不良的生理变化并增加对疾病的易感性,明确引发衰老的机制对于寻找其干预措施至关重要。研究发现,自由基氧化应激、炎症性衰老、免疫衰老、肠道菌群失调是引发衰老的相关机制。益生菌被报道具有潜在的延缓衰老作用,比较分析了常用益生菌抗衰老评价模型,并从衰老引发机制出发,重点综述了益生菌对肠道菌群的调节机制和抗衰老相关信号通路的影响,旨为进一步研究益生菌抗衰老作用提供新思路。     

腹泻及其微生态防治的相关进展

益生菌可能对不同病因引起的不同类型的腹泻有预防的疗效.已经成功的通过调查各种各样的益生菌和确立益生菌性质来证明其对健康的益处和预防、治疗(或缓和)腹泻的作用.其它有益生作用的微生物、某些双歧杆菌、肠球菌以及益生菌酵母菌属的酵母菌作为单个株或复合益生菌在其药用方面的价值也得到肯定.本文主要综述了益生菌在腹泻方面的治疗作用和机制.     

Probiotics and small bowel mucosa: Molecular aspects of their interactions

Probiotics are described as "friendly bacteria" that could improve the intestine defense by interacting with the resident microflora. There is a large body of evidence suggesting that consumption of functional food containing probiotics exerts positive effects on human health. Several clinical trials have highlighted the efficiency of probiotics in the prevention and treatment of different gastrointestinal disorders including the prevention of antibiotic associated diarrhea, the remission in patients with inflammatory bowel disease, beneficial effects against Helicobacter pylori infection, positive effects in patients affected by allergies and atopic diseases. The clinical benefits of probiotics use are mainly attributed to their antimicrobial substances production and their positive interactions with the enterocytes to reinforce the intestinal epithelial barrier. Moreover, there is evidence suggesting that probiotics stimulate both specific and non-specific host immune responses. Recently, have been published some experiments performed with the DNA microarray technology which provided a global gene screening of the complex bacteria-host interplay. Nevertheless, the molecular mechanisms by which probiotics enhance the intestinal host defense are still not completely elucidated. Here, we review the experiments and clinical studies to date on the complex mechanisms regulating the communication between probiotics and their hosts.     

富硒益生菌的功效研究进展

硒是人体必需的微量元素,对人体健康有重要作用。益生菌能够将硒元素转化为有机硒,降低硒的毒性,同时硒又提高了益生菌的生物活性,富硒益生菌具备了硒和益生菌的双重功效。本文主要综述了近年来富硒益生菌的功效,如抗氧化、抑制有害菌、调节肠道菌群、抗癌等。     

益生菌的免疫调节作用及其相关应用研究进展

益生菌的定义来自希腊语,益生菌是指:当摄入足够的剂量时可以对宿主产生有益影响的活的微生物。目前,全球对益生菌及其相关制剂的研究日益受到重视,益生菌在食品、营养品及医药领域的研究也不断深入,益生菌的免疫调节机制主要包括黏膜屏障作用、增强单核—巨噬细胞的吞噬作用、促进sIgA生成等。此外,益生菌还应用于临床相关疾病的治疗,改善受损肝脏的功能,缓解肠易激综合征的临床症状,通过调节脂肪代谢及胰岛素敏感性预防2型糖尿病的发生,预防结直肠肿瘤细胞生长及减轻肠道炎症等。本文主要就益生菌的上述相关研究进展进行综述,为益生菌的研究及相关应用提供参考。     

Anti-Adhesion Effects of Lactobacillus Strains on Caco-2 Cells Against Escherichia Coli and Their Application in Ameliorating the Symptoms of Dextran Sulfate Sodium-Induced Colitis in Mice

The beneficial effects of probiotics on ameliorating ulcerative colitis (UC) have attracted much attention in recent years. Nevertheless, the number of these identified probiotics is still limited. In addition, the adhesion abilities of probiotics are considered to be a key determinant for probiotic efficacy. However, the relationship between the adhesion abilities of probiotics and their role in ameliorating UC has been poorly studied to date. This study measured the adhesion abilities of four Lactobacillus strains to Caco-2 cells and their anti-adhesion effects on Caco-2 cells against pathogenic bacteria, as well as their application in ameliorating the symptoms of dextran sulfate sodium-induced UC, and further illustrated the relationship between these two potential probiotic properties of probiotics and their beneficial effects on UC. Results suggested that the adhesion abilities of the four tested Lactobacillus strains exists highly strain-specific and the mechanisms of their anti-adhesion effect on Caco-2 cells against Escherichia coli may be different. Moreover, all these strains had promising effects on ameliorating UC by reducing inflammatory response and improving the intestinal mucosal barrier function, as well as promoting the production of SCFAs. In conclusion, the four tested Lactobacillus strains can be considered as alternative dietary supplements in alleviating UC. In addition, it could be concluded that there is no significant correlation between the adhesion abilities of probiotics and their role in ameliorating UC, which further illustrated that the adhesion properties of probiotics in vitro may not be suitable as the key criterion for screening potential strains with UC-alleviating effects.

     

复合益生菌体外抑菌杀病毒作用研究

采用平板抑菌法和液体试管法来研究复合益生菌对蜡样芽胞杆菌和伤寒沙门菌的作用。另外,通过提取复合益生菌与肠道病毒作用前后的总RNA并用RT-PCR扩增-琼脂糖凝胶电泳的方法来研究两者的作用。结果显示,复合益生菌对致病性蜡样芽胞杆菌和伤寒沙门菌具有明显的抑制作用,对肠道病毒具有杀灭作用。     

A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action

A number of investigations, mainly using in vitro and animal models, have demonstrated a wide range of possible mechanisms, by which probiotics may play a role in colorectal cancer (CRC) prevention. In this context, the most well studied probiotics are certain strains from the genera of lactobacilli and bifidobacteria. The reported anti-CRC mechanisms of probiotics encompass intraluminal, systemic, and direct effects on intestinal mucosa. Intraluminal effects detailed in this review include competitive exclusion of pathogenic intestinal flora, alteration of intestinal microflora enzyme activity, reduction of carcinogenic secondary bile acids, binding of carcinogens and mutagens, and increasing short chain fatty acids production. Reduction of DNA damage and suppression of aberrant crypt foci formation have been well demonstrated as direct anti-CRC effects of probiotics on intestinal mucosa. Existing evidence clearly support a multifaceted immunomodulatory role of probiotics in CRC, particularly its ability to modulate intestinal inflammation, a well known risk factor for CRC. The effectiveness of probiotics in CRC prevention is dependent on the strain of the microorganism, while viability may not be a prerequisite for certain probiotic anticancer mechanisms, as indicated by several studies. Emerging data suggest synbiotic as a more effective approach than either prebiotics or probiotics alone. More in vivo especially human studies are warranted to further elucidate and confirm the potential role of probiotics (viable and non-viable), prebiotics and synbiotics in CRC chemoprevention.     

Selenium-Enriched Probiotics Improves Murine Male Fertility Compromised by High Fat Diet

A total of 75 male mice were allotted to five groups of 15 each in a completely randomized experimental design to study the effects of probiotics, inorganic selenium, and selenium-enriched probiotics on male fertility in hyperlipidemic status. The mice in group 1 were fed a normal basal diet and served as negative control. The mice in group 2 were fed a high fat diet and served as positive control. The mice in groups 3, 4, and 5 were fed the high fat diet supplemented with probiotics, inorganic selenium, and selenium-enriched probiotics, respectively. The high fat diet was composed of 15% lard, 1% cholesterol, 0.3% cholic acid, and 83.7% basal diet. Over 90% of the selenium in the selenium-enriched probiotics was present in forms of organic selenium. After the mice were fed these diets for 75 days, serumal total cholesterol, triglycerides, low density lipoprotein, high density lipoprotein, and testosterone levels, plus sperm index (count, motility and abnormalities), penis length, and weight and histopathology of testes were measured. The results showed that in the mice fed the high fat diet were significant (P < 0.01) elevations of serumal total cholesterol, triglycerides and low density lipoprotein, and decreases of high density lipoprotein. The high fat diet caused a decline in serumal testosterone level, reduced semen quality, and atrophy and degeneration of seminiferous tubules. No effects on penis length or relative weight of testis were observed. Supplementation of probiotics, inorganic selenium, or selenium-enriched probiotics to the high fat diet significantly alleviated (P < 0.05) the adverse effects of hyperlipidemia by reducing testicular tissue injury, increasing serumal testosterone level, and improving sperm indexes. It was concluded that hyperlipidemia had significant adverse effects on male fertility, which could be ameliorated at various degrees by feeding the diets supplemented with probiotics, inorganic selenium, or selenium-enriched probiotics. Selenium-enriched probiotics or inorganic selenium supplementation gave better results than probiotics supplementation and may be used to improve animal and human male fertility compromised by hyperlipidemia or obesity.     

益生菌对自身免疫病的作用及机制研究现状

自身免疫病是机体免疫功能紊乱而导致组织器官受损的一类疾病,包括类风湿关节炎、系统性红斑狼疮、多发性硬化症、自身免疫性肝炎等。糖皮质激素及免疫抑制剂是治疗自身免疫病的常用药物,但长期使用会产生代谢紊乱、免疫低下、继发感染等副作用。随着肠道菌群与自身免疫病相关研究的进展,益生菌干预自身免疫病成为一大研究热点。研究证实,益生菌缓解自身免疫病安全有效,有望成为辅助疗法甚至替代疗法。本文就益生菌缓解类风湿关节炎、系统性红斑狼疮、多发性硬化症、自身免疫性肝炎等的作用及相关机制进行综述。     

现代生物技术与饲用微生态制剂

近年来,使用抗生素的副作用越来越多地受到关注,世界上许多国家已出台相应政策来控制抗生素的使用。但是由于养殖行业的迅猛发展,养殖密度加大,养殖动物病害发病的风险提高,急需可替代抗生素的新型绿色饲料添加剂产品。微生态制剂作为一种新型绿色饲料添加剂,在养殖行业发挥了重要作用。随着饲用微生态制剂产品研发的深入,现代生物技术在提升微生态制剂的理论和应用研究方面发挥着重要作用。PCR、核酸分子杂交、基因工程以及组学等技术已应用于微生物菌种鉴定、基因改良、作用机理等研究中。本文对饲用微生态制剂的研发现状进行了阐述,并综述了现代生物技术在饲用微生态制剂研究中的应用。     

益生菌的功能基因导入和基因编辑

益生菌已经在临床和食品领域应用多年,其安全性和有效性已经获得人们的认可。随着分子生物学技术的发展,采用益生菌作为载体进行基因导入或基因编辑,这些遗传改造的益生菌一部分已经作为新的药品或疫苗进入到临床应用阶段。携带功能基因的益生菌定殖于肠道进行表达和缓慢释放,这类益生菌作为活体药物获得益生菌和功能基因的双重功效,可用于治疗某些疑难病症。携带蛋白质抗原基因的益生菌定殖于肠道进行表达,可诱导肠道黏膜免疫、细胞免疫和体液免疫,这是一条更安全的口服疫苗途径。成簇的规则间隔短回文重复序列(clustered regularly interspaced short palindromic repeats, CRISPR)及其相关蛋白(CRISPR-associated protein, Cas)以其高效与便捷性推动了益生菌基因编辑的发展。这篇综述介绍了CRISPR-Cas9操作系统在益生菌方面的应用。对传统遗传操作较难的益生菌采用CRISPR-Cas9技术进行基因编辑,使其基因敲除和基因突变,基因敲入和基因调控等更为简单、高效和易操作。这些CRISPR/Cas9、CRISPRa和CRISPRi技术在...     

Probiotics in human health and disease: from nutribiotics to pharmabiotics

Probiotics are the most useful tools for balancing the gut microbiota and thereby influencing human health and disease. Probiotics have a range of effects, from those on nutritional status to medical conditions throughout the body from the gut to non-intestinal body sites such as the brain and skin. Research interest in probiotics with nutritive claims (categorized as nutribiotics) has evolved into interest in therapeutic and pharmacological probiotics with health claims (pharmabiotics). The concept of pharmabiotics emerged only two decades ago, and the new categorization of probiotics to nutribiotics and pharmabiotics was recently suggested, which are under the different regulation depending on that they are food or drug. Information of the gut microbiome has been continuously accumulating, which will make possible the gut microbiome-based healthcare in the future, when nutribiotics show potential for maintaining health while pharmabiotics are effective therapeutic tools for human diseases. This review describes the current understanding in the conceptualization and classification of probiotics. Here, we reviewed probiotics as nutribiotics with nutritional functions and pharmabiotics with pharmaceutic functions in different diseases.     

Probiotics and their fermented food products are beneficial for health

Probiotics are usually defined as microbial food supplements with beneficial effects on the consumers. Most probiotics fall into the group of organisms' known as lactic acid-producing bacteria and are normally consumed in the form of yogurt, fermented milks or other fermented foods. Some of the beneficial effect of lactic acid bacteria consumption include: (i) improving intestinal tract health; (ii) enhancing the immune system, synthesizing and enhancing the bioavailability of nutrients; (iii) reducing symptoms of lactose intolerance, decreasing the prevalence of allergy in susceptible individuals; and (iv) reducing risk of certain cancers. The mechanisms by which probiotics exert their effects are largely unknown, but may involve modifying gut pH, antagonizing pathogens through production of antimicrobial compounds, competing for pathogen binding and receptor sites as well as for available nutrients and growth factors, stimulating immunomodulatory cells, and producing lactase. Selection criteria, efficacy, food and supplement sources and safety issues around probiotics are reviewed. Recent scientific investigation has supported the important role of probiotics as a part of a healthy diet for human as well as for animals and may be an avenue to provide a safe, cost effective, and 'natural' approach that adds a barrier against microbial infection. This paper presents a review of probiotics in health maintenance and disease prevention.     

Evolving Roles of Probiotics in Cancer Prophylaxis and Therapy

In nutraceutical science, the ingestible live microbes ‘probiotics’ are regarded for their ability to confer multiplicity of health benefits on the consumers. Wide spectrum impact of these friendly microbes on the host health has been proved very frequently. They have been confirmed to boost immunity, aid in digestion, eliminate pathogens, curb inflammatory bowel diseases, moderate side effects of antibiotic therapy, lower cholesterol and blood glycemic index and produce vitamins. This review, however, focuses on the incipient, but promising area of probiotic diet-based prevention and remedy of cancer. Researchers are in universal agreement with the critical role of probiotics in getting rid of mutagens, delaying the onset of tumors, alleviating the side effects, pepping up chemotherapy, easing the postoperative complications, foiling remission and lifting the spirit of survivors. The key findings in the emerging roles of probiotics in onco-care have been summarized; the biological pathways discussed and anticipated developments in coming times are presented.     

微生态制剂干预肠易激综合征患者疗效meta分析

目的对微生态制剂干预肠易激综合征患者的疗效进行系统性分析,指导临床用药。方法联机检索Medline、维普、万方数据库、CNKI、CBMdisc中微生态制剂治疗肠易激综合征疗效的随机对照临床试验,对文献质量进行严格评价和资料提取,对符合质量标准的RCT进行Meta分析。结果共有7项研究符合入选标准,其中5项研究提示微生态制剂干预肠易激综合征患者疗效不优于安慰剂,2项研究认为微生态制剂有效改善患者的临床症状,荟萃结果表明微生态制剂可以有效缓解肠易激综合征临床症状[OR(95%CI):1.66(1.27,2.18)]。结论微生态制剂可以有效缓解肠易激综合征临床症状。     

益生菌的研究进展及其在食品中的应用

益生菌是一类能够促进宿主肠内微生物菌群的生态平衡,对宿主健康和/或生理功能产生有益作用的活性微生物。本文就益生菌概念的发展演变、益生菌种类及其在食品中的应用研究进展进行了综述,旨在为读者提供益生菌在食品领域研究应用的基本情况及其发展趋势。     

Probiotics–pathogen interactions elicit differential regulation of cutaneous immune responses in epidermal cells of Atlantic cod Gadus morhua

Little is known on the cutaneous immune responses during probiotics–pathogen interactions in fish. Thus, this study employed Atlantic cod primary epidermal (EP) cell cultures as a model to understand this interaction. The probiotics–pathogen interactions in the EP cell cultures were elucidated using Vibrio anguillarum 2133 (VA) as the pathogen and two host-derived bacteria (GP21 and GP12) as the probiotics. There was a regional size difference on the EP cells; i.e., EP cells from the dorsal region were significantly larger than the EP cells at the ventral side. VA significantly decreased viability of EP cells. In the presence of probiotics, this inhibition was mitigated. The probiotics reduced VA-induced cellular apoptosis and the probiotics–pathogen interactions influenced cellular myeloperoxidase activity during the latter stage of co-incubation. The probiotics–pathogen interactions triggered differential regulation of immune-related genes and the effects of the interaction were dependent on the region where the cells were isolated and the length of the co-incubation period. In most cases, the presence of probiotics alone showed no significant change on the mRNA level of immune genes in the EP cells but triggered immunostimulatory activity when incubated with VA. This study showed that the virulence of VA in EP cells could be modulated by host-derived probiotics and the immunomodulatory characteristics of the two candidate probionts advanced their immune-related probiotic potential.     

国内益生菌制剂清除幽门螺杆菌感染临床疗效的Meta分析

目的对益生菌制剂清除幽门螺杆菌（H.pylori）感染的临床疗效及其对治疗中抗生素相关的不良反应的改善情况进行系统评价。方法通过计算机检索CBMdisc、CNKI、VIP以及MEDLINE等数据库,全面收集中国地区应用益生菌制剂治疗且pylori感染的随机或半随机对照试验,并按Cochrane协作网推荐的方法对其进行Meta分析。并评价Meta分析结果的稳定性和发表偏倚。结果纳入15个试验包括1572例病人,对尼py／or／清除率和不良反应改善情况分别进行Meta分析显示,试验组Hpylori清除率（88．53％）明显高于对照组（82．73％）（合并OR为1．56,95％CI为1．17—2．08,总体效应检验,Z=2．99,P=0．003）;不良反应发生率分别为5．O％和24．3％,合并OR为0．16,95％cI为0．09—0．31,表明能显著改善治疗中的不良反应发生情况,且差异具有显著性。结论联合应用益生菌制剂可以提高抗皿pylori感染治疗中的清除率,单独应用益生菌制剂清除且pylori感染也有一定的疗效。同时,益生菌制剂对且pylori感染治疗中的不良反应有较显著的改善。益生菌制剂有可能对Hpylori感染及相关疾病的防治具有重要意义。